Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENSITIZE study of domatinostat plus pembrolizumab in anti-PD-1-refractory advanced cutaneous melanoma
2017-001050-33Phase 2Completed
- Sponsor
- 4SC AG
- Start
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Domatinostat, pembrolizumab in cutaneous melanoma (CM), sponsored by 4SC AG. Started Jun 2017; status: completed.
02
Drugs
Domatinostatpembrolizumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2017-001050-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001050-33.